Search research articles
Contact Us
Filters
Showing results (51-60 of 68) with videos related to
Page
of 7
Sort By:
Food Research International (Ottawa, Ont.)
|
November 1, 2025
Functional differentiation of Sojae semen Praeparatum: A multi-omics analysis of the effects of Artemisia annua and Mori folium on composition, microorganisms, and functional characteristics
Yingying Cheng, Bing Wang, Qiaoling Ma, et al.
Chemosphere
|
August 26, 2023
Low transplacental transfer of PFASs in the small-for-gestational-age (SGA) new-borns: Evidence from a Chinese birth cohort
Yijun Fan, Liyan Guo, Ruolan Wang, et al.
Oncology Reports
|
May 11, 2023
Nucleophosmin promotes lung adenocarcinoma cell proliferation, migration and invasion by activating the EGFR/MAPK signaling pathway
Min Li, Rongrong Wu, Dongyi Zhu, et al.
Aging
|
January 24, 2024
Usenamine A triggers NLRP3/caspase-1/GSDMD-mediated pyroptosis in lung adenocarcinoma by targeting the DDX3X/SQSTM1 axis
Min Li, Rongrong Wu, Le Wang, et al.
Materials (Basel, Switzerland)
|
May 13, 2026
Microstructure and Property Modification of High-Strength Martensitic Steel Through Plasma Arc Remelting
Yan Liu, Shilian Hu, Jianwen Huang, et al.
Breast Cancer Research : BCR
|
April 17, 2026
Prediction of pathologic upstaging in ductal carcinoma in situ using MRI radiomics combined with clinicopathological features
Chengliu Bi, Qinqing Li, Lijuan Deng, et al.
Antimicrobial Agents and Chemotherapy
|
August 3, 2011
Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes
Kendra E Hightower, Ruolan Wang, Felix Deanda, et al.
Open Forum Infectious Diseases
|
July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis
Stefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
Viruses
|
June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
Cell Reports
|
June 29, 2024
Molecular basis for the activation of PAF receptor by PAF
Wenjia Fan, Youwei Xu, Xinheng He, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 68) with videos related to
Sort By:
Page
of 7
Food Research International (Ottawa, Ont.)
|
November 1, 2025
Functional differentiation of Sojae semen Praeparatum: A multi-omics analysis of the effects of Artemisia annua and Mori folium on composition, microorganisms, and functional characteristics
Yingying Cheng, Bing Wang, Qiaoling Ma, et al.
Chemosphere
|
August 26, 2023
Low transplacental transfer of PFASs in the small-for-gestational-age (SGA) new-borns: Evidence from a Chinese birth cohort
Yijun Fan, Liyan Guo, Ruolan Wang, et al.
Oncology Reports
|
May 11, 2023
Nucleophosmin promotes lung adenocarcinoma cell proliferation, migration and invasion by activating the EGFR/MAPK signaling pathway
Min Li, Rongrong Wu, Dongyi Zhu, et al.
Aging
|
January 24, 2024
Usenamine A triggers NLRP3/caspase-1/GSDMD-mediated pyroptosis in lung adenocarcinoma by targeting the DDX3X/SQSTM1 axis
Min Li, Rongrong Wu, Le Wang, et al.
Materials (Basel, Switzerland)
|
May 13, 2026
Microstructure and Property Modification of High-Strength Martensitic Steel Through Plasma Arc Remelting
Yan Liu, Shilian Hu, Jianwen Huang, et al.
Breast Cancer Research : BCR
|
April 17, 2026
Prediction of pathologic upstaging in ductal carcinoma in situ using MRI radiomics combined with clinicopathological features
Chengliu Bi, Qinqing Li, Lijuan Deng, et al.
Antimicrobial Agents and Chemotherapy
|
August 3, 2011
Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes
Kendra E Hightower, Ruolan Wang, Felix Deanda, et al.
Open Forum Infectious Diseases
|
July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis
Stefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
Viruses
|
June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
Cell Reports
|
June 29, 2024
Molecular basis for the activation of PAF receptor by PAF
Wenjia Fan, Youwei Xu, Xinheng He, et al.
Page
of 7